Halozyme Therapeutics Inc
NASDAQ:HALO
Halozyme Therapeutics Inc
NASDAQ:HALO
Price:
40.3 USD
1.21%
Updated:
May 3, 2024
Halozyme Therapeutics Inc
Net Income (Common)
|
Halozyme Therapeutics Inc
Net Income (Common) Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
Net Income (Common)
$281.6m
|
CAGR 3-Years
30%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$484m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-20%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is Halozyme Therapeutics Inc's Net Income (Common)?
Net Income (Common)
281.6m
USD
281.6m
USD
Based on the financial report for Dec 31, 2023, Halozyme Therapeutics Inc's Net Income (Common) amounts to 281.6m USD.
What is Halozyme Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
30%
30%
Over the last year, the Net Income (Common) growth was 39%. The average annual Net Income (Common) growth rates for Halozyme Therapeutics Inc have been 30% over the past three years .
You don't have any saved screeners yet
